MRZM Stock Overview
A multi-technology biomedical company, develops and commercializes medical technologies to enhances patients health. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Marizyme, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.016 |
| 52 Week High | US$0.13 |
| 52 Week Low | US$0.016 |
| Beta | -0.019 |
| 1 Month Change | -64.44% |
| 3 Month Change | -67.96% |
| 1 Year Change | -89.33% |
| 3 Year Change | -99.10% |
| 5 Year Change | -96.92% |
| Change since IPO | -99.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| MRZM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -27.3% | -3.3% | -2.2% |
| 1Y | -89.3% | -1.9% | 23.9% |
Return vs Industry: MRZM underperformed the US Biotechs industry which returned -1.9% over the past year.
Return vs Market: MRZM underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| MRZM volatility | |
|---|---|
| MRZM Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MRZM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine MRZM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 13 | David Barthel | www.marizyme.com |
Marizyme, Inc., a multi-technology biomedical company, develops and commercializes medical technologies to enhances patients health. It’s product portfolio includes DuraGraft, a first-in-class, De Novo granted and CE marked intra-operative vascular graft storage and flushing solution used during coronary artery bypass graft (CABG) surgeries; MATLOC, a point-of-care, lab-on-chip technology platform, developed for quantitative chronic kidney disease assessment; and Krillase, a protein enzyme that acts to break protein bonds and has applications in wound debridement, wound healing, dental care and thrombosi. The company also engages in the development of MAR-FG-001, a fat grafting technology for the use during fat grafting procedures.
Marizyme, Inc. Fundamentals Summary
| MRZM fundamental statistics | |
|---|---|
| Market cap | US$2.11m |
| Earnings (TTM) | -US$52.51m |
| Revenue (TTM) | US$364.95k |
5.8x
P/S Ratio0.0x
P/E RatioIs MRZM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRZM income statement (TTM) | |
|---|---|
| Revenue | US$364.95k |
| Cost of Revenue | US$131.37k |
| Gross Profit | US$233.58k |
| Other Expenses | US$52.75m |
| Earnings | -US$52.51m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 64.00% |
| Net Profit Margin | -14,389.51% |
| Debt/Equity Ratio | -208.5% |
How did MRZM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 14:49 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Marizyme, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|